Deciphering immune heterogeneity in lung adenocarcinoma via machine learning-based Differential Phenotype Immune Score: TPX2 as a key biomarker for immunotherapy resistance.

Abstract excerpt

Background: Immune heterogeneity is a major determinant of clinical outcome and immunotherapy responsiveness in lung adenocarcinoma (LUAD). However, the tumor-intrinsic transcriptional programs that drive immune divergence across patients remain insufficiently characterized. Methods: We constructed an integrated immune landscape of LUAD by combining bulk transcriptomic data, multi-omics profiling, and a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenocarcinoma of Lung
• Share to Biomarkers, Tumor